Houston, United States
Research view
Switch to patient viewThyroid cancer: who works on it
Groups that published on this disease or run trials on it, from public registries and publications. Researchers appear by name only once their profile is published.
Find fellow researchers
One card per institution. Pick a target to see only the groups that work on it.
- All targets
- BRAF 15
- RET 8
- PI3K 0
- TP53 0
- TERT 0
- MAPK 1
- GLP-1 1
- AKT 0
- PTEN 0
- STAT3 0
- mTOR 0
- NTRK 2
- PD-1 5
- RAS 1
- ERK 0
- MEK 1
- PSMA 1
- ALK 1
- EGFR 3
- VEGF 2
- PD-L1 0
- JAK 0
- KRAS 1
- CTNNB1 0
- NRAS 2
- NRF2 0
- PPAR 0
- TROP2 3
- AMPK 0
- DLL3 2
- HIF-1 0
- PIK3CA 0
- ABL1 0
- DPP-4 0
- IL-6 1
- METTL3 0
- TNF 0
- YAP 0
- AXL 1
- EZH2 0
- FGFR 0
- JNK 0
- MET 1
- MYC 0
- PKM2 0
- ROS1 1
- SGLT2 0
- STING 0
- ATM 0
- BRCA1 0
- BRCA2 0
- BRD4 0
- CDKN2A 0
- CGRP 0
- CTLA-4 0
- CXCR4 0
- FAK 0
- GPX4 0
- HMGB1 0
- IDH 0
Seoul, South Korea
Cleveland Clinic · Cleveland, United States
Team details appear once the team leader joins.
Is this your team? Claim it
Latest publication · Clin Cancer Res, Mar 2026Landscape of Genomic Mechanisms of Resistance to Selective RET Inhibitors in RET-Altered Solid Tumors: Analysis of the RETgistry Global Consortium.
San Francisco, United States
Atlanta, United States
Chicago, United States
Seoul, South Korea
Toronto, Canada
Durham, United States
Duarte, United States
Coral Gables, United States
11 of 11+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.
Running research funding
Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.
European Commission (Horizon Europe) · HORIZON-ERC
ALK-driven cancers: a Portfolio of ONcoimmunoTherapies to achieve tumor Eradication (A-PONTE)
The disease is named only in the funder's project summary, not in the title.
European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-GF
Chemotherapy-induced Alopecia - Relief Managed by Engineered Silk (CARMESilk)
The disease is named only in the funder's project summary, not in the title.
European Commission (Horizon Europe) · HORIZON-CSA
3 of 3 running projects, newest first. Listed amounts together: €7.8m.
Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.
Who stopped a trial, and why
Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.
Terminated
Study of IK-595 in RAS- or RAF-altered Advanced Tumors
“Limited resources and strategic priorities”Registry text, quoted unchanged. Source
Trials that share participant data
Trials whose registry record says individual participant data (IPD) will be shared.
No trial in this view states that it shares participant data.
Search by method
Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.
- Single-Cell Analysis 24
- Organoids 6
- Mendelian Randomization Analysis 16
- CRISPR-Cas Systems 3
- Gene Expression Profiling 65
- Sequence Analysis, RNA 7
- Whole Genome Sequencing 1
- Exome Sequencing 7
- Proteomics 14
- Metabolomics 9
- Mass Spectrometry 7
- Flow Cytometry 6
- Immunohistochemistry 72
- Liquid Biopsy 9
- Circulating Tumor DNA 3
- Xenograft Model Antitumor Assays 57
- Positron-Emission Tomography 44
- Magnetic Resonance Imaging 18
- Machine Learning 72
- Deep Learning 44
- Cohort Studies 118
- Genome-Wide Association Study 16
Paste an abstract
See which targets of this disease your abstract mentions, and go to the people working on them.
Matched in your browser only. The text is not sent, saved or logged.
Sources: ClinicalTrials.gov, EU CTR, OpenAlex, PubMed, NIH RePORTER, CORDIS. Machine-matched links are labelled.